HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pallone, Pitts Committed To Cosmetics Legislation In “This Congress”

This article was originally published in The Rose Sheet

Executive Summary

During a markup of an FDA user-fee bill, legislators from both sides of the aisle affirmed their intent to tackle cosmetics regulation in a separate, stand-alone bill later this year. The user-fee bill omitted a section that was in place previously to implement cosmetics user fees.

You may also be interested in...



NPA Assumes Expanded Role: Advocate For Natural Cosmetics

The Natural Products Association has convened the first meeting of a committee to guide lobbying and advocacy work for personal-care members. NPA has actively backed the dietary supplement industry in legislative matters and now looks to provide similar support to natural/organic manufacturers facing a handful of cosmetics safety bills.

In Brief

Under an amendment to the FDA Safety and Innovation Act, which passed the U.S. Senate May 24, there will be no further delays in implementation of FDA’s final rule for sunscreen testing and labeling. More news in brief.

Generics: Capitol Hill’s Super “Pay For”

As the user fee legislation continues its remarkably tranquil journey with a unanimous vote in the House Energy & Commerce Committee, tweaks to the ANDA review process have helped smooth some of the rough edges.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018094

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel